Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Serine beta-lactamases (class A) are enzymes produced by bacteria that confer resistance to beta-lactam antibiotics, such as penicillins and cephalosporins, by hydrolyzing the characteristic beta-lactam ring of these drugs. This enzymatic activity renders the antibiotics ineffective, allowing bacteria to survive in their presence. The catalytic process involves two main steps: acylation and deacylation. Notable examples include TEM-1, SHV, CTX-M, and KPC-type enzymes. These enzymes are major contributors to bacterial resistance against widely used antibiotics. They are found predominantly in Gram-negative bacteria but also occur in some Gram-positive species like staphylococci. Class A serine β-lactamases can often be inhibited by compounds such as clavulanic acid or tazobactam; however, some variants show reduced susceptibility or resistance even to these inhibitors.
Acylation–deacylation via nucleophilic attack on β-lactam ring
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Serine beta-Lactamase (Class A).